title: Increase in methotrexate dose in patients with rheumatoid arthritis who have an inadequate response to infliximab.
authors.forename: P
authors.initials: P
authors.lastname: Ornetti
authors.forename: E
authors.initials: E
authors.lastname: Solau
authors.forename: P
authors.initials: P
authors.lastname: Gaudin
authors.forename: J
authors.initials: J
authors.lastname: Sibilia
authors.forename: J-M
authors.initials: JM
authors.lastname: Berthelot
authors.forename: X
authors.initials: X
authors.lastname: Puechal
authors.forename: C
authors.initials: C
authors.lastname: Tavernier
authors.forename: J F
authors.initials: JF
authors.lastname: Maillefert
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage*; D008875:Middle Aged; D017211:Treatment Failure; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D008727:Methotrexate